Rapid health technology evaluation of trastuzumab deruxtecan in the treatment of advanced or metastatic breast cancer
JIANG Yi
ZHANG Zhuo
LIU Qian-xin
ZHANG Zhi-qi
LIU Xiao
ZHOU Ying
Abstract：Objective:To evaluate the efficacy,safety and pharmacoeconomic of trastuzumab deruxtecan ( T-DXd) in the treatment of advanced or metastatic breast cancer. Methods:Databases in Chinese/English and websites on health technology assessment ( HTA ) were systematically searched. Two reviewers independently identified the studies,extracted data,and accessed the quality. Descriptive statistical analysis was conducted. Results:5 HTA reports,19 Meta-analyses/systematic reviews,and 14 economic studies were included. In the second-line treatment of human epidermal growth factor receptor 2 positive advanced or metastatic breast cancer,T-DXd demonstrated superior efficacy compared to trastuzumab emtansine ( T-DM1 ) . Common adverse events associated with T-DXd included gastrointestinal reactions,hematologic toxicity,fatigue,and alopecia. Notably,interstitial lung disease was a specific adverse event. Due to drug price restrictions,T-DXd was not cost-effective compared with T-DM1 or chemotherapy for Chinese payers. Conclusion:T-DXd has favorable efficacy and controllable safety,but is not economical at present.
Keywords：trastuzumab deruxtecanbreast cancereffectivenesssafetyeconomyrapid health technology assessment
Publication Date：2025-01-14
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：8( 102-109 )